Globus Medical (NYSE:GMED) Stock Price Down 6.5% – What’s Next?

Globus Medical, Inc. (NYSE:GMED) shares were down 6.5% during mid-day trading on Tuesday . The company traded as low as $76.88 and last traded at $78.46. 192,185 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 1,434,343 shares. The stock had previously closed at $83.94.

Analyst Upgrades and Downgrades

GMED has been the topic of a number of recent analyst reports. Needham & Company LLC boosted their price target on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wells Fargo & Company decreased their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Finally, Royal Bank Of Canada boosted their target price on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Globus Medical currently has an average rating of “Moderate Buy” and a consensus target price of $105.00.

Globus Medical Stock Performance

The company’s 50 day moving average price is $83.39 and its 200-day moving average price is $87.37. The company has a market cap of $10.57 billion, a price-to-earnings ratio of 18.11, a PEG ratio of 1.78 and a beta of 0.95.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period in the prior year, the business earned $0.68 earnings per share. The business’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current year.

Insider Activity

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the transaction, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 18.38% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently modified their holdings of GMED. Sanctuary Advisors LLC grew its stake in shares of Globus Medical by 2.3% in the first quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after buying an additional 151 shares in the last quarter. SBI Securities Co. Ltd. raised its position in Globus Medical by 98.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after acquiring an additional 167 shares in the last quarter. Parallel Advisors LLC raised its position in Globus Medical by 45.1% during the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the last quarter. Finally, Allworth Financial LP lifted its stake in Globus Medical by 1.6% in the fourth quarter. Allworth Financial LP now owns 12,545 shares of the medical device company’s stock valued at $1,095,000 after acquiring an additional 199 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.